These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 34683998)

  • 1. Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives.
    Martín-Sabroso C; Lozza I; Torres-Suárez AI; Fraguas-Sánchez AI
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
    Kondrashov A; Sapkota S; Sharma A; Riano I; Kurzrock R; Adashek JJ
    Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
    Nerone M; Grande MD; Sessa C; Colombo I
    Explor Target Antitumor Ther; 2022; 3(2):149-171. PubMed ID: 36046840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating antibody drug conjugates in the management of gynecologic cancers.
    Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
    Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel antibody-drug conjugates: current and future roles in gynecologic oncology.
    Tymon-Rosario J; Zeybek B; Santin AD
    Curr Opin Obstet Gynecol; 2021 Feb; 33(1):26-33. PubMed ID: 32618744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
    McGuinness JE; Kalinsky K
    Expert Opin Biol Ther; 2021 Jul; 21(7):903-913. PubMed ID: 33089726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unveiling the antibody-drug conjugates portfolio in battling Triple-negative breast cancer: Therapeutic trends and Future horizon.
    Khadela A; Soni S; Shah AC; Pandya AJ; Megha K; Kothari N; Cb A
    Med Oncol; 2022 Dec; 40(1):25. PubMed ID: 36456774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
    Adams E; Wildiers H; Neven P; Punie K
    ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Drug Conjugates in Gynecologic Cancer.
    Karpel HC; Powell SS; Pothuri B
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
    Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
    Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.
    Nagayama A; Ellisen LW; Chabner B; Bardia A
    Target Oncol; 2017 Dec; 12(6):719-739. PubMed ID: 29116596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.
    Nwabufo CK
    Cancer Chemother Pharmacol; 2024 Feb; 93(2):89-105. PubMed ID: 37594572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
    Nader-Marta G; Molinelli C; Debien V; Martins-Branco D; Aftimos P; de Azambuja E; Awada A
    Ther Adv Med Oncol; 2023; 15():17588359231183679. PubMed ID: 37435563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development.
    Koster KL; Huober J; Joerger M
    Explor Target Antitumor Ther; 2022; 3(1):27-36. PubMed ID: 36046357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Drug Conjugates for Breast Cancer.
    Marmé F
    Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond.
    Barroso-Sousa R; Tolaney SM
    BioDrugs; 2021 Mar; 35(2):159-174. PubMed ID: 33666903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.
    Ascione L; Crimini E; Trapani D; Marra A; Criscitiello C; Curigliano G
    Oncologist; 2023 Nov; 28(11):944-960. PubMed ID: 37665782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.